Treatment Information

Back

Breast Cancer treatment details. Chemotherapy, Biologic therapy.

Indiana University Cancer Center, Indianapolis, IN, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Indianapolis, IN
Treatments:Chemotherapy, Biologic therapyHospital:Indiana University Cancer Center
Drugs:Journal:Link
Date:Dec 2007

Description:

Patients: This phase 3 study involved 722 women with metastatic breast cancer. They ranged in age from 27 to 85 years of age. The majority had estrogen receptor positive tumors.

Treatment: These women were treated with the chemotherapy drug paclitaxel alone or in combination with the biological therapy bevacizumab (a monoclonal antibody).

Toxicity: Grade 4 allergic reaction, fatigue, febrile neutropenia, cerebrovascular ischemia, and sensory neuropathy were reported. Grade 3 toxicities included allergic reaction, febrile neutropenia, infection, fatigue, hypertension, sensory neuropathy, and nausea.

Results: The median overall survival was 26.7 months in women receiving paclitaxel and bevacizumab and 25.2 months for those receiving paclitaxel alone.

Support: This study was supported in part by Genentech, which markets bevacizumab as Avastin“.

Correspondence: Dr. Kathy Miller



Back